Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C7H11NO4 |
Molecular Weight | 173.1665 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 2 / 2 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CC(=O)N1C[C@H](O)C[C@H]1C(O)=O
InChI
InChIKey=BAPRUDZDYCKSOQ-RITPCOANSA-N
InChI=1S/C7H11NO4/c1-4(9)8-3-5(10)2-6(8)7(11)12/h5-6,10H,2-3H2,1H3,(H,11,12)/t5-,6+/m1/s1
Oxaceprol, a structural analog of hydroxyproline, has been used for several years for the treatment of osteoarthritis and rheumatoid arthritis, showing good gastrointestinal safety, particularly in comparison with NSAIDs. It was shown that oxaceprol does not inhibit the synthesis of prostaglandins in vitro, but acts predominantly by inhibiting leukocyte adhesion and migration, thus inhibiting inflammation at an early stage and helps in pain relief.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: GO:0007159 Sources: https://www.ncbi.nlm.nih.gov/pubmed/10423160 |
|||
Target ID: GO:0050900 Sources: https://www.ncbi.nlm.nih.gov/pubmed/10423160 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Palliative | Unknown Approved UseUnknown |
|||
Palliative | Unknown Approved UseUnknown |
PubMed
Title | Date | PubMed |
---|---|---|
Oxaceprol is as effective as diclofenac in the therapy of osteoarthritis of the knee and hip. | 1999 |
|
Antirheumatic agents and leukocyte recruitment. New light on the mechanism of action of oxaceprol. | 1999 Jul 15 |
|
Oxaceprol is a well-tolerated therapy for osteoarthritis with efficacy equivalent to diclofenac. | 2000 |
|
Oxaceprol, an atypical inhibitor of inflammation, reduces leukocyte adherence in mouse antigen-induced arthritis. | 2001 Jun |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/10791619
for 21 days with 400 mg t.i.d. oxaceprol
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/2281302
It was studied the effect of oxaceprol on the synthesis and degradation of proteoglycans and proteins by calf articular cartilage explants. The effect was observed at concentrations 10(-6) M to 10(-9) M, i.e. at 170 ng to 170 pg of the oxaceprol per ml of culture media, respectively. However, no significant effect was seen at concentrations 10(-4) M (17 micrograms/ml) to 10(-8) M (1.7 ng/ml) on the protein and proteoglycan catabolism.
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Systematic Name | English | ||
|
Official Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-VATC |
QM01AX24
Created by
admin on Fri Dec 15 16:11:05 GMT 2023 , Edited by admin on Fri Dec 15 16:11:05 GMT 2023
|
||
|
WHO-VATC |
QD11AX09
Created by
admin on Fri Dec 15 16:11:05 GMT 2023 , Edited by admin on Fri Dec 15 16:11:05 GMT 2023
|
||
|
NCI_THESAURUS |
C257
Created by
admin on Fri Dec 15 16:11:05 GMT 2023 , Edited by admin on Fri Dec 15 16:11:05 GMT 2023
|
||
|
WHO-ATC |
M01AX24
Created by
admin on Fri Dec 15 16:11:05 GMT 2023 , Edited by admin on Fri Dec 15 16:11:05 GMT 2023
|
||
|
WHO-ATC |
D11AX09
Created by
admin on Fri Dec 15 16:11:05 GMT 2023 , Edited by admin on Fri Dec 15 16:11:05 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
33996-33-7
Created by
admin on Fri Dec 15 16:11:05 GMT 2023 , Edited by admin on Fri Dec 15 16:11:05 GMT 2023
|
PRIMARY | |||
|
C90905
Created by
admin on Fri Dec 15 16:11:05 GMT 2023 , Edited by admin on Fri Dec 15 16:11:05 GMT 2023
|
PRIMARY | |||
|
SUB09483MIG
Created by
admin on Fri Dec 15 16:11:05 GMT 2023 , Edited by admin on Fri Dec 15 16:11:05 GMT 2023
|
PRIMARY | |||
|
65784
Created by
admin on Fri Dec 15 16:11:05 GMT 2023 , Edited by admin on Fri Dec 15 16:11:05 GMT 2023
|
PRIMARY | |||
|
OXACEPROL
Created by
admin on Fri Dec 15 16:11:05 GMT 2023 , Edited by admin on Fri Dec 15 16:11:05 GMT 2023
|
PRIMARY | |||
|
251-780-6
Created by
admin on Fri Dec 15 16:11:05 GMT 2023 , Edited by admin on Fri Dec 15 16:11:05 GMT 2023
|
PRIMARY | |||
|
3891
Created by
admin on Fri Dec 15 16:11:05 GMT 2023 , Edited by admin on Fri Dec 15 16:11:05 GMT 2023
|
PRIMARY | |||
|
DB13363
Created by
admin on Fri Dec 15 16:11:05 GMT 2023 , Edited by admin on Fri Dec 15 16:11:05 GMT 2023
|
PRIMARY | |||
|
Q0XV76B96L
Created by
admin on Fri Dec 15 16:11:05 GMT 2023 , Edited by admin on Fri Dec 15 16:11:05 GMT 2023
|
PRIMARY | |||
|
DTXSID2046410
Created by
admin on Fri Dec 15 16:11:05 GMT 2023 , Edited by admin on Fri Dec 15 16:11:05 GMT 2023
|
PRIMARY | |||
|
100000083577
Created by
admin on Fri Dec 15 16:11:05 GMT 2023 , Edited by admin on Fri Dec 15 16:11:05 GMT 2023
|
PRIMARY | |||
|
2005
Created by
admin on Fri Dec 15 16:11:05 GMT 2023 , Edited by admin on Fri Dec 15 16:11:05 GMT 2023
|
PRIMARY | |||
|
28068
Created by
admin on Fri Dec 15 16:11:05 GMT 2023 , Edited by admin on Fri Dec 15 16:11:05 GMT 2023
|
PRIMARY | RxNorm | ||
|
Q0XV76B96L
Created by
admin on Fri Dec 15 16:11:05 GMT 2023 , Edited by admin on Fri Dec 15 16:11:05 GMT 2023
|
PRIMARY | |||
|
m8272
Created by
admin on Fri Dec 15 16:11:05 GMT 2023 , Edited by admin on Fri Dec 15 16:11:05 GMT 2023
|
PRIMARY | Merck Index | ||
|
CHEMBL2105621
Created by
admin on Fri Dec 15 16:11:05 GMT 2023 , Edited by admin on Fri Dec 15 16:11:05 GMT 2023
|
PRIMARY |
ACTIVE MOIETY